RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 07, 2026 SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that […]

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation

iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation GlobeNewswire January 07, 2026 NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P. Morgan

Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference

Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 07, 2026 NOVATO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D.,

Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 07, 2026 SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Jane Chung, Chief Executive Officer,

Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis Investor call to be held January 8 at 4:30 pm ET to discuss data update and next steps GlobeNewswire January 07, 2026 PITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc.

INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP announces that Firefly Aerospace Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP announces that Firefly Aerospace Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit GlobeNewswire January 07, 2026 SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Firefly Aerospace Inc. (NASDAQ: FLY):

Ethan Allen Announces Release Date for its Fiscal 2026 Second Quarter Results

Ethan Allen Announces Release Date for its Fiscal 2026 Second Quarter Results GlobeNewswire January 07, 2026 DANBURY, CT, Jan. 07, 2026 (GLOBE NEWSWIRE) — Ethan Allen Interiors Inc. (“Ethan Allen” or the “Company”) (NYSE: ETD) will release its financial and operational results for the fiscal 2026 second quarter ended December 31, 2025, after the stock

Abivax Provides 2026 Corporate Outlook

Abivax Provides 2026 Corporate Outlook GlobeNewswire January 07, 2026 Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD space ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found

Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors

Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company's Strategic Long-Term Goals for Growth and Expansion GlobeNewswire January 07, 2026 LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) — Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage

Definitive Healthcare to Present at the 28th Annual Needham Growth Conference

Definitive Healthcare to Present at the 28th Annual Needham Growth Conference GlobeNewswire January 07, 2026 FRAMINGHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) — Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare market data and analytics, today announced that its Chief Financial Officer, Casey Heller, will present at the 28th Annual Needham Growth Conference. The

Scroll to Top